19 September 2017 in Science Signaling
Editing of FAK mRNA by the enzyme ADAR in lung adenocarcinoma cells promotes migration and invasion.
23 January 2024 in European Journal of Cardio-Thoracic Surgery
OBJECTIVES: Recent randomized data support the perioperative benefits of minimally invasive surgery (MIS) for non-small-cell lung cancer (NSCLC). Its utility for cT4 tumours remains understudied. We, therefore, sought to analyse national trends and outcomes of minimally invasive resections for cT4 cancers. METHODS: Using the 2010–2019 National Cancer Database, we identified patients with cT4N0-1 NSCLC. Patients were stratified by surgical approach. Multivariable logistic analysis was used to identify factors associated with use of a minimally invasive approach. Groups were matched using propensity score analysis to evaluate perioperative and survival end points. RESULTS: The study identified 3715 patients, among whom 64.1% (n = 2381) underwent open resection and 35.9% (n = 1334) minimally invasive resection [robotic-assisted in 31.5% (n = 420); and video-assisted in 68.5% (n = 914)]. Increased MIS use was noted among patients with higher income [≥$40 227, odds ratio (OR) 1.24; 95% confidence interval (CI) 1.01–1.51] and those treated at academic hospitals (OR 1.25; 95% CI 1.07–1.45). Clinically node-positive patients (OR 0.68; 95% CI 0.55–0.83) and those who underwent neoadjuvant therapy (OR 0.78; 95% CI 0.65–0.93) were less likely to have minimally invasive resection. In matched groups, patients undergoing MIS had a shorter median length of stay (5 vs 6 days, P < 0.001) and no significant differences between 30-day readmissions or 30/90-day mortality. MIS did not compromise overall survival (log-rank P = 0.487). CONCLUSIONS: Nationally, the use of minimally invasive approaches for patients with cT4N0-1M0 NSCLC has increased substantially. In these patients, MIS is safe and does not compromise perioperative outcomes or survival.
1 June 2023 in Thoracic Surgery Clinics
7 February 2025 in Thoracic Surgery Clinics
15 October 2025 in Thoracic Surgery Clinics
13 February 2026 in JTCVS Open
JRJorge Humberto Rodriguez-Quintero
Jorge Humberto Rodriguez-Quintero
+6
Randomized data support the mortality benefit of lung cancer screening (LCS); however, completion rates among those meeting eligibility criteria remain concerningly low. The Distressed Communities Index (DCI) is a composite socioeconomic metric assessed by ZIP code. We sought to investigate the association between DCI and completion of scheduled LCS appointments. A retrospective study was conducted in patients scheduled for LCS with low-dose computed tomography at a high-volume center in 2021. Patients were marked as a “no-show” when they missed or canceled their scheduled screening appointment. The association between DCI and screening no-show rates was modeled using a stepwise approach. A total of 1114 patients were scheduled for LCS, of whom 83.5% (n = 928) resided in ZIP codes considered “at-risk” or “distressed” in terms of socioeconomic distress based on their DCI score. In the entire cohort, 18.4% of patients (n = 205) did not attend any screening appointments scheduled within the year. Patients in the “at-risk” and “distressed” categories were more likely to have a no-show (19.5% vs 12%; P = .015). A higher DCI score was associated with increased probability of screening noncompletion on univariable analysis (odds ratio [OR], 1.02; 95% confidence interval [CI], 1.01-1.03; P = .002). On multivariable analysis, additional factors associated with higher likelihood of a no-show included current smoking status (adjusted OR [aOR], 2.59; 95% CI, 1.70-3.96) and initial screening (aOR, 2.07; 95% CI, 1.43-3.00). Higher DCI scores are associated with increased no-show rates for LCS appointments. This tool can be used to target populations at risk of underscreening and associated lung cancer mortality with navigational support or novel interventions to increase screening.